A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia
Critical Care2009Vol. 13(2), pp. R36–R36
Citations Over TimeTop 10% of 2009 papers
Pierre-François Laterre, Steven M. Opal, Edward Abraham, Steven P. LaRosa, Abla A. Creasey, Fang Xie, Lona Poole, Richard G. Wunderink
Abstract
ClinicalTrials.gov identifier NCT00084071.
Related Papers
- → The Effects of Incorporating a Pneumonia Severity Index into the Admission Protocol for Community-Acquired Pneumonia(2010)18 cited
- Mortality predictors in community-acquired pneumonia.(2009)
- → Comparison of pneumonia severity scoring methods in identification of severe community acquired pneumonia(2017)1 cited
- [Community-acquired pneumonia caused by biological pathogens].(2012)
- → On the importance of premorbid conditions in the onset of acute pneumonia in young children(1981)